ReviewGastroenterology research and practice2026
Diagnostic and Prognostic Biomarkers for Sepsis-Associated Liver Injury: Current Status and Future Perspectives.
Review in Gastroenterology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic and Prognostic Biomarkers for Sepsis-Associated Liver Injury: Current Status and Future Perspectives.Gastroenterology research and practice · 2026Review
- Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated liver injury (SALI) is a complication of sepsis that carries a notably poor prognosis in the intensive care unit (ICU). So far, there remains no specific consensus regarding the diagnostic criteria for SALI. The quest for biomarkers associated with SALI continues, as they are essential for both early diagnosis and prognostic assessment. Traditionally utilized biomarkers include alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin; however, their lack of specificity and sensitivity has hindered the accurate diagnosis of SALI and the prediction of subsequent disease progression. Recently, novel biomarkers such as microRNAs, differentially expressed genes (DEGs), and high mobility group protein B1 (HMGB1) have been explored to enhance the early diagnosis and prognostic prediction of SALI. However, each of these biomarkers presents certain limitations. This review is aimed at summarizing the aforementioned biomarkers with the hope that future researchers will identify the most effective markers for diagnosing SALI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.